| S.No |
Lesion |
No. of cases |
No. of positive cases |
Cumulative score |
| Negative |
Weakly positive |
Strongly positive |
Mean ± SD |
| |
4-Jan |
>4 |
| 0 |
|
|
| Group I |
|
|
|
|
|
|
|
| Benign |
Pleomorphic adenoma |
8 |
8 |
- |
8 |
- |
1.8 ± 0.64 |
| Malignant |
Peripheral mucoepidermoid carcinoma |
5 |
5 |
- |
4 |
1 |
3.4± 1.95 |
| Central mucoepidermoid carcinoma |
4 |
4 |
- |
4 |
|
2 ± 1.414 |
| Adenocarcinoma nos |
2 |
2 |
- |
2 |
- |
2.5 ± 2.121 |
| PLGA |
1 |
1 |
- |
1 |
- |
1 |
| Total |
12 |
12 |
- |
11 |
1 |
2.58 ± 1.72 |
A total of 20 cases formed the study group out of which Group I (Benign) comprising of 8 cases and group II (Malignant) comprising of 12 cases were each immunohistochemically
stained for Bcl-2. All 8 cases of group I was positive and showed weak positivity. In group II, all 12 cases were positive and the expression varied from weak to intense with
1 case showing strong positive Bcl-2 expression. Overall, malignant tumours showed a more intense Bcl-2 expression compared to benign tumours. |
